Y-ECCO Literature Reviews
30April2019

Y-ECCO Literature Review: Aravind Gokul Tamilarasan

Aravind Gokul Tamilarasan

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in Inflammatory Bowel Disease

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B

Aliment Pharmacol Ther. 2019;49:880–9

Aravind Gokul Tamilarasan
Aravind Gokul Tamilarasan 
© Aravind Gokul Tamilarasan

Introduction

Since the publication of the landmark SONIC trial in 2010 [1], the use of combination biologic–immunomodulator therapy has been considered best standard practice for patients with Inflammatory Bowel Disease (IBD) who have failed topical therapies or immunomodulators (thiopurines or methotrexate). More recently, real-world data from the PANTS (Personalised anti-TNF therapy in Crohn’s Disease) study demonstrated the benefit of combination therapy (particularly for infliximab) in the form of higher week 54 remission rates and prevention of immunogenicity [2]. Notably, the week 54 remission rates were independent of infliximab trough levels or immunogenicity status, suggesting additional benefits apart from improving the pharmacokinetics of infliximab. This study aimed to provide further real-world data on the effect of combination therapy on clinical and pharmacokinetic outcomes.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review: James Gauci

James Gauci

Risankizumab in patients with moderate to severe Crohn's Disease: An open-label extension study

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO

Lancet Gastroenterol Hepatol. 2018;3:671–80. DOI: https://doi.org/10.1016/S2468-1253(18)30233-4   

James Gauci
James Gauci 
© James Gauci

Introduction

Management of Crohn’s Disease involves the suppression of inflammation through administration of immunosuppressive drugs. While conventional therapies such as corticosteroids and thiopurines exert a broad effect on the immune system, the advent of biological agents has allowed for selective targeting of cytokines and integrins.

Unfortunately, a third of patients treated with tumour necrosis factor (TNF) antagonists demonstrate a primary non-response, with another third developing either secondary failure or intolerance. These patients will then have a lower chance of responding to treatment with other TNF antagonists or with the integrin antagonist vedolizumab.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review: Ivan Lyutakov

Ivan Lyutakov

Serum Concentration of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease

Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland L, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS

Clin Gastroenterol Hepatol. 2018 Nov 15. doi:10.1016/j.cgh.2018.11.012    

Ivan Lyutakov
Ivan Lyutakov 
© Ivan Lyutakov

Introduction

Inflammatory Bowel Disease (IBD) comprises a heterogeneous group of chronic inflammatory disorders with two main conditions, Crohn’s Disease (CD) and Ulcerative Colitis (UC) [1]. Bile acid malabsorption (BAM) and bile acid diarrhoea (BAD) have been recognised to be a common cause of chronic diarrhoea, and this recognition has led to the initiation of a search for new screening tests (biomarkers). BAM is one of the mechanisms leading to microscopic colitis, a key factor in the pathogenesis of irritable bowel syndrome-diarrhoea, and molecular mechanisms of BAM are found in IBD patients with or without involvement of the terminal ileum. BAM/BAD is more frequently found in CD than in UC, and the obvious aetiology for BAM in CD is either ileal resection or ileal disease [2]. The pathophysiology of diarrhoea in CD is multifactorial but there are two key factors, colonic water and electrolyte absorption, which can be impaired directly by colonic inflammation or indirectly by increased concentrations of bile acids having secretory effects, referred to as BAD [3].

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

30April2019

Y-ECCO Literature Review Introduction

Mark Samaan, Y-ECCO Literature Review Admin

Mark Samaan 2019
Mark Samaan 
© ECCO

 

Dear Y-ECCO Friends,

A warm welcome to the Y-ECCO Literature Review section, where you will find a summary and discussion of cutting-edge clinical trials as well as basic science studies in the field of IBD. 

If you are a Y-ECCO Member and you are looking for an opportunity to get actively involved in ECCO and gain some visibility, contribute your article to the Y-ECCO Literature Review corner, together with a short self-description and your picture.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 14, Issue 1, Y-ECCO

11December2018

Y-ECCO Literature Review: Sasha Fehily

Sasha Fehily

CALM Trial

Sasha Fehily
Sasha Fehily 
© ECCO

Introduction

There has been a recent shift in Crohn’s Disease (CD) management away from the conventional focus on short-term clinical outcomes and towards the maintenance of long-term remission.  In 2015 the International Organisation for the Study of Inflammatory Bowel Diseases released a consensus statement recommending a treat-to-target approach [1]. The STRIDE initiative recommended pursuing treatment escalation in order to achieve the treatment targets of clinical remission and mucosal healing, with adjunctive use of normal C-reactive protein (CRP) and faecal calprotectin (FC) levels. However, the authors noted that prospective studies would be needed to confirm that achievement of these targets would alter the natural history of disease and improve patients’ quality of life.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 4, Y-ECCO

11December2018

Y-ECCO Literature Review Introduction

Dominik Bettenworth, Y-ECCO Literature Review Admin

Dominik Bettenworth 2
Dominik Bettenworth 
© ECCO

 

Dear Y-ECCO Friends,

A warm welcome to the Y-ECCO Literature Review section, where you will find a summary and discussion of cutting-edge clinical trials as well as basic science studies in the field of IBD. 

If you are a Y-ECCO Member and you are looking for an opportunity to get actively involved in ECCO and gain some visibility, contribute your article to the Y-ECCO Literature Review corner, together with a short self-description and your picture.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 4, Y-ECCO

04October2018

Y-ECCO Literature Review: Christina Kapizioni

Christina Kapizioni

13 Y ECCO Lit Review Christina Kapizioni
Christina Kapizioni 
© 
Christina Kapizioni

Increased risk of acute arterial events in young patients and severely active IBD: A nationwide French cohort study

Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M; BERENICE study group
Gut. 2018;67:1261–1268.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 3, Y-ECCO

04October2018

Y-ECCO Literature Review Introduction

Dominik Bettenworth, Y-ECCO Literature Review Admin

Dominik Bettenworth 2
Dominik Bettenworth
© ECCO

 

Dear Y-ECCO Friends,

A warm welcome to the Y-ECCO Literature Review section, where you will find a summary and discussion of cutting-edge clinical trials as well as basic science studies in the field of IBD. 

If you are a Y-ECCO Member and you are looking for an opportunity to get actively involved in ECCO and gain some visibility, contribute your article to the Y-ECCO Literature Review corner, together with a short self-description and your picture.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 3, Y-ECCO

08June2018

Y-ECCO Literature Review: Viktor Domislović

Viktor Domislović

13 3 ViktorViktor Domislović 
© 
Viktor Domislović

Cumulative burden of inflammation predicts colorectal neoplasia risk in Ulcerative Colitis: A large single-centre study

Choi CR, Al Bakir I, Ding NJ, Lee GH, Askari A, Warusavitarne J, Moorghen M, Humphries A, Ignjatovic-Wilson A, Thomas-Gibson S, Saunders BP, Rutter MD, Graham TA, Hart AL
Gut. 2017 Nov 17. pii: gutjnl-2017-314190. doi: 10.1136/gutjnl-2017-314190.

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 2, Y-ECCO

08June2018

Y-ECCO Literature Review: Valentina Petito

Valentina Petito

13 4 V.Petito
Valentina Petito
© Valentina Petito

Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in Inflammatory Bowel Disease

Häsler R, Sheibani-Tezerji R, Sinha A, Barann M, Rehman A, Esser D, Aden K, Knecht C, Brandt B, Nikolaus S, Schäuble S, Kaleta C, Franke A, Fretter C, Müller W, Hütt MT, Krawczak M, Schreiber S, Rosenstiel P
Gut. 2017;66:2087–2097. doi:10.1136/gutjnl-2016-311651

Posted in Y-ECCO Literature Reviews, ECCO News, Committee News, Volume 13, Issue 2, Y-ECCO